<DOC>
	<DOCNO>NCT00732316</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy antithymocyte globulin donor stem cell transplant help stop growth cancer abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . PURPOSE : This phase II trial study well donor stem cell transplant work busulfan , fludarabine , antithymocyte globulin treat patient hematologic cancer myelodysplastic syndrome .</brief_summary>
	<brief_title>Donor Stem Cell Transplant After Busulfan , Fludarabine , Antithymocyte Globulin Treating Patients With Hematologic Cancer Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy HLA-haploidentical familial donor hematopoietic cell transplantation reduced-intensity condition regimen busulfan , fludarabine phosphate , anti-thymocyte globulin patient hematologic malignancy myelodysplastic syndrome . OUTLINE : Before receive reduced-intensity conditioning regimen , patient receive one dose intrathecal ( IT ) methotrexate , leucovorin calcium IV orally 4 hour methotrexate every 6 hour total 8 dos . - Reduced-intensity conditioning regimen : Patients receive busulfan IV 6 hour day -7 -6 , fludarabine phosphate IV 30 minute day -7 -2 , anti-thymocyte globulin ( ATG ) IV 4 hour day -4 -1 , methylprednisolone IV 30 minute day -4 -1 . - HLA-haploidentical familial donor hematopoietic stem cell transplantation ( HSCT ) : Patients undergo allogeneic HSCT 1 hour day 0 1 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV* 2-4 hour every 12 hour day -1 30 followed taper day 60 methotrexate IV day 2 , 4 , 7 , 12 . NOTE : *Cyclosporine give orally oral medication tolerate - CNS prophylaxis : When blood count recover , patient acute leukemia chronic myelogenous leukemia blastic crisis resume IT methotrexate every 2 week total 4 dos ( include dose give condition regimen ) leucovorin calcium IV orally 4 hour ( dose methotrexate ) every 6 hour total 8 dos . After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematological malignancy : Acute leukemia , include follow : Refractory acute leukemia Acute leukemia beyond first remission Acute leukemia first remission intermediate poor prognostic feature suggest chromosomal finding Chronic myelogenous leukemia ( CML ) Second chronic phase Accelerated phase Blastic phase Myelodysplastic syndrome ( MDS ) Highrisk MDS ( refractory anemia excess blast [ RAEB ] , RAEB transformation , chronic myelomonocytic leukemia ) transplant without prior therapy prior therapy failure hypomethylating agent Lowrisk MDS consider transplantation prior therapy failure immunosuppressive hypomethylating agent No willing , suitable HLAmatched donor family donor registry Patients active hematologic malignancy , felt urgent need allogeneic hematopoietic cell transplantation , enroll without search HLAmatched unrelated donor Related donor HLAhaploidentical mismatch 3 less 6 loci available PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 2.0 mg/dL Creatinine &lt; 2.0 mg/dL AST &lt; 3 time upper limit normal Ejection fraction &gt; 40 % MUGA PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>